A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant
Regeneron Pharmaceuticals
Summary
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Eligibility
- Age range
- 18–70 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\]. 2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944 3. Willing and able to comply with clinic visits and study-related procedures 4. Provide informed consent signed by study patient or legally acceptable representative Exclusion Criteria: 1.There are no exclusion criteria for this study. Note: Other protocol defined Inclusion/Exclusion criteria may apply
Interventions
- DrugNoninterventional
No investigational treatment will be given in this noninterventional extension study
Locations (9)
- Cedars-Sinai Medical CenterLos Angeles, California
- University of California IrvineOrange, California
- Connie Frank Transplant Center at UCSFSan Francisco, California
- Yale University of MedicineNew Haven, Connecticut
- Comprehensive Transplant CenterChicago, Illinois
- John Hopkins HospitalBaltimore, Maryland